Therapeutic group
|
N
|
DT (days; AM ± SE)*
|
GD (days; AM ± SE)**
|
Cures†(%; n)
|
SC resistance#
|
---|
Control
|
12
|
1.7 ± 0.2
|
-
|
0
| |
EP
|
13
|
4.2 ± 0.6
|
2.5 ± 0.6
|
0
| |
dsRed
|
12
|
3.1 ± 0.3
|
1.3 ± 0.3
|
0
| |
EGT dsRed
|
14
|
5.3 ± 0.9
|
3.5 ± 0.9
|
0
| |
mIL-12
|
13
|
3.1 ± 0.4
|
1.4 ± 0.4
|
0
| |
EGT mIL12
|
14
|
20.0 ± 3.0 ‡
|
18.3 ± 3.0
|
7.1 (1/14)
|
0/1
|
IR
|
13
|
5.4 ± 0.9
|
3.7 ± 0.9
|
0
| |
EP + IR
|
14
|
14.4 ± 4.2 ‡
|
12.7 ± 4.2
|
0
| |
dsRed + IR
|
9
|
5.3 ± 1.1
|
3.6 ± 1.1
|
0
| |
EGT dsRed + IR
|
11
|
9.3 ± 1.9
|
7.5 ± 1.9
|
0
| |
mIL-12 + IR
|
13
|
10.7 ± 1.7
|
8.9 ± 1.7
|
0
| |
EGT mIL-12 + IR
|
14
|
32.6 ± 4.3 ‡§
|
30.9 ± 4.3 §
|
21.4 (3/14)
|
1/3
|
- Therapeutic groups: 10 Gy single dose irradiation (IR), electrical pulse application alone (EP) or combined with irradiation (EP + IR), intratumoral injection of plasmid DNA coding for mIL-12 or dsRed alone (mIL-12, dsRed) or combined with irradiation (mIL-12 + IR, dsRed + IR), mIL-12 or dsRed gene electrotransfer alone (EGT mIL-12, EGT dsRed) or combined with irradiation (EGT mIL-12 + IR, EGT dsRed + IR).
- N - Number of all mice in the group.
- * - Tumor doubling time - only mice with tumors were included in calculation.
- ** - Tumor growth delay - only mice with tumors were included in calculation.
-
† - Cures were determined 100 days after the treatment.
-
# - Resistance to secondary challenge – number of cured mice that were resistant to secondary challenge is shown.
-
‡
-
- Statistical significant difference compared to control group (p < 0.05).
-
§ - Statistical significant difference compared to IR (p < 0.05).